|
Jul 29
|
Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board
|
|
Jul 22
|
Replimune drug rejected by FDA; Omega raises $647M biotech fund
|
|
Jul 21
|
iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right
|
|
May 28
|
iTeos Therapeutics Announces Its Intention to Wind Down Operations
|
|
May 28
|
Cancer drugmaker iTeos to shut down
|
|
May 14
|
GSK and iTeos drop anti-TIGIT drug following trial failure
|
|
May 13
|
iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile
|
|
May 13
|
GSK, iTeos Therapeutics End Belrestotug Development Program
|
|
May 13
|
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
|
|
Mar 13
|
Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet
|
|
Aug 8
|
ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 8
|
iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates
|
|
Aug 5
|
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
|
|
May 10
|
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
|
|
May 10
|
iTeos Therapeutics Announces $120 Million Registered Direct Offering
|
|
May 10
|
iTeos shares jump on TIGIT update; Acelyrin swaps CEOs
|
|
Apr 7
|
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
|
|
Mar 6
|
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
|
|
Mar 6
|
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
|
|
Mar 5
|
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
|